These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 22314205)

  • 21. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
    Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
    Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patient-reported outcomes for acute graft-versus-host disease prevention and treatment trials.
    Lee SJ; Williams LA
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):295-300. PubMed ID: 19747556
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of an immunoglobulin preparation enriched for IgM (Pentaglobin) for the treatment of acute graft-versus-host disease.
    Klingemann HG; Barnett MJ; Reece DE; Shepherd JD; Phillips GL
    Bone Marrow Transplant; 1990 Sep; 6(3):199-202. PubMed ID: 2252960
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alternate applications of immunoglobulin following bone marrow transplantation.
    Copelan EA; Avalos BR; Kapoor N; Bechtel T; Tutschka PJ
    Semin Hematol; 1992 Jul; 29(3 Suppl 2):96-9. PubMed ID: 1324531
    [No Abstract]   [Full Text] [Related]  

  • 25. A new marrow T cell depletion method using anti-CD6 monoclonal antibody-conjugated magnetic beads and its clinical application for prevention of acute graft-vs.-host disease in allogeneic bone marrow transplantation: results of a phase I-II trial.
    Sao H; Kitaori K; Kasai M; Shimokawa T; Kato C; Yamanishi H; Ueda R; Morishima Y
    Int J Hematol; 1999 Jan; 69(1):27-35. PubMed ID: 10641440
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Titrating graft-versus-host disease: is it worth a try?
    Akpek G
    Bone Marrow Transplant; 2006 Nov; 38(10):653-6. PubMed ID: 17006455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Suicide gene therapy and the control of graft-vs-host disease.
    Introna M; Rambaldi A
    Best Pract Res Clin Haematol; 2004 Sep; 17(3):453-63. PubMed ID: 15498716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention of graft-versus-host disease by lymphocyte depletion of the bone marrow graft with use of counterflow centrifugation.
    Haanen C; De Witte T; Plas A; Schattemberg T
    Haematologica; 1991 Mar; 76 Suppl 1():22-8. PubMed ID: 1864551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT.
    Ruutu T; Niederwieser D; Gratwohl A; Apperley JF
    Bone Marrow Transplant; 1997 Apr; 19(8):759-64. PubMed ID: 9134165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allogeneic bone marrow transplantation compared to peripheral blood stem cell transplantation for the treatment of hematologic malignancies: a meta-analysis based on time-to-event data from randomized controlled trials.
    Chang YJ; Weng CL; Sun LX; Zhao YT
    Ann Hematol; 2012 Mar; 91(3):427-37. PubMed ID: 21789620
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predicting the severity of graft-versus-host disease from interleukin-10 levels after bone marrow transplantation.
    Takatsuka H; Takemoto Y; Okamoto T; Fujimori Y; Tamura S; Wada H; Okada M; Yamada S; Kanamaru A; Kakishita E
    Bone Marrow Transplant; 1999 Nov; 24(9):1005-7. PubMed ID: 10556960
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methodologic issues in investigation of targeted therapies in acute myeloid leukemia.
    Estey E
    Adv Pharmacol; 2004; 51():99-106. PubMed ID: 15464906
    [No Abstract]   [Full Text] [Related]  

  • 33. Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation.
    Atkinson K; Downs K
    Bone Marrow Transplant; 1995 Dec; 16(6):755-8. PubMed ID: 8750265
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conditioning-related toxicity and acute graft-versus-host disease in patients given methotrexate/cyclosporine prophylaxis.
    Deeg HJ; Spitzer TR; Cottler-Fox M; Cahill R; Pickle LW
    Bone Marrow Transplant; 1991 Mar; 7(3):193-8. PubMed ID: 2059756
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive factors for chronic graft-versus-host disease after histocompatible sibling donor bone marrow transplantation.
    Ochs LA; Miller WJ; Filipovich AH; Haake RJ; McGlave PB; Blazar BR; Ramsay NK; Kersey JH; Weisdorf DJ
    Bone Marrow Transplant; 1994 Apr; 13(4):455-60. PubMed ID: 8019471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of acute graft-vs-host disease by a single low-dose cyclophosphamide injection following allogeneic bone marrow transplantation.
    Prigozhina TB; Elkin G; Khitrin S; Slavin S
    Exp Hematol; 2008 Dec; 36(12):1750-9. PubMed ID: 18809241
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Graft-versus-host disease in allogeneic bone marrow transplantation: the role of monoclonal antibodies in prevention and treatment.
    Hiscott A; McLellan DS
    Br J Biomed Sci; 2000; 57(2):163-9. PubMed ID: 10912294
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blockade of acute grade IV skin and eye graft-versus-host disease by anti-interleukin-2 receptor monoclonal antibody in genoidentical bone marrow transplantation setting.
    Ozşahin H; Tuchschmid P; Lauener R; Waldvogel K; Nadal D; Seger RA
    Turk J Pediatr; 1998; 40(2):231-5. PubMed ID: 9677728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction of oral tolerance in bone marrow transplantation recipients suppresses graft-versus-host disease in a semiallogeneic mouse model.
    Nagler A; Ohana M; Alper R; Doviner V; Sherman Y; Rabbani E; Engelhardt D; Ilan Y
    Bone Marrow Transplant; 2003 Aug; 32(4):363-9. PubMed ID: 12900772
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proliferation-based T-cell selection for immunotherapy and graft-versus-host-disease prophylaxis in the context of bone marrow transplantation.
    Pachnio A; Dietrich S; Klapper W; Humpe A; Schwake M; Sedlacek R; Gramatzki M; Beck C
    Bone Marrow Transplant; 2006 Jul; 38(2):157-67. PubMed ID: 16820783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.